Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker GOSS
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 6, 2026 | SCHEDULE 13G/A (amended) | GOSS Gossamer Bio, Inc. | James Silverman | 426,989 | 7.0% | SCHEDULE 13G/A ↗ |
| Nov 6, 2026 | SCHEDULE 13G/A (amended) | GOSS Gossamer Bio, Inc. | Opaleye, L.P. | 415,000 | 6.8% | SCHEDULE 13G/A ↗ |
| Nov 6, 2026 | SCHEDULE 13G/A (amended) | GOSS Gossamer Bio, Inc. | Opaleye Management Inc. | 426,989 | 7.0% | SCHEDULE 13G/A ↗ |
| Nov 6, 2026 | SCHEDULE 13G | GOSS Gossamer Bio, Inc. | Abigail P. Johnson | 667,465 | 10.9% | SCHEDULE 13G ↗ |
| Nov 6, 2026 | SCHEDULE 13G | GOSS Gossamer Bio, Inc. | FMR LLC | 667,465 | 10.9% | SCHEDULE 13G ↗ |
| Oct 29, 2026 | SCHEDULE 13D/A (amended) | GOSS Gossamer Bio, Inc. | David E. Shaw | 255,431 | 4.2% | SCHEDULE 13D/A ↗ |
| Oct 29, 2026 | SCHEDULE 13D/A (amended) | GOSS Gossamer Bio, Inc. | D. E. Shaw & Co., L.P. | 255,431 | 4.2% | SCHEDULE 13D/A ↗ |
| Oct 29, 2026 | SCHEDULE 13D/A (amended) | GOSS Gossamer Bio, Inc. | D. E. Shaw & Co., L.L.C. | 255,431 | 4.2% | SCHEDULE 13D/A ↗ |
| Oct 29, 2026 | SCHEDULE 13D/A (amended) | GOSS Gossamer Bio, Inc. | D. E. Shaw Valence Portfolios, L.L.C. | 243,041 | 4.0% | SCHEDULE 13D/A ↗ |
| Oct 8, 2026 | SCHEDULE 13D/A (amended) | GOSS Gossamer Bio, Inc. | David E. Shaw | 369,459 | 6.0% | SCHEDULE 13D/A ↗ |
| Oct 8, 2026 | SCHEDULE 13D/A (amended) | GOSS Gossamer Bio, Inc. | D. E. Shaw & Co., L.P. | 369,459 | 6.0% | SCHEDULE 13D/A ↗ |
| Oct 8, 2026 | SCHEDULE 13D/A (amended) | GOSS Gossamer Bio, Inc. | D. E. Shaw & Co., L.L.C. | 369,459 | 6.0% | SCHEDULE 13D/A ↗ |
| Oct 8, 2026 | SCHEDULE 13D/A (amended) | GOSS Gossamer Bio, Inc. | D. E. Shaw Valence Portfolios, L.L.C. | 358,693 | 5.9% | SCHEDULE 13D/A ↗ |
| Sep 28, 2026 | SCHEDULE 13D/A (amended) | GOSS Gossamer Bio, Inc. | David E. Shaw | 312,048 | 5.1% | SCHEDULE 13D/A ↗ |
| Sep 28, 2026 | SCHEDULE 13D/A (amended) | GOSS Gossamer Bio, Inc. | D. E. Shaw & Co., L.P. | 312,048 | 5.1% | SCHEDULE 13D/A ↗ |
| Sep 28, 2026 | SCHEDULE 13D/A (amended) | GOSS Gossamer Bio, Inc. | D. E. Shaw & Co., L.L.C. | 312,048 | 5.1% | SCHEDULE 13D/A ↗ |
| Sep 28, 2026 | SCHEDULE 13D/A (amended) | GOSS Gossamer Bio, Inc. | D. E. Shaw Valence Portfolios, L.L.C. | 296,858 | 4.9% | SCHEDULE 13D/A ↗ |
| Aug 24, 2026 | SCHEDULE 13D/A (amended) | GOSS Gossamer Bio, Inc. | David E. Shaw | 29.13M | 6.0% | SCHEDULE 13D/A ↗ |
| Aug 24, 2026 | SCHEDULE 13D/A (amended) | GOSS Gossamer Bio, Inc. | D. E. Shaw & Co., L.P. | 29.13M | 6.0% | SCHEDULE 13D/A ↗ |
| Aug 24, 2026 | SCHEDULE 13D/A (amended) | GOSS Gossamer Bio, Inc. | D. E. Shaw & Co., L.L.C. | 29.13M | 6.0% | SCHEDULE 13D/A ↗ |
| Aug 24, 2026 | SCHEDULE 13D/A (amended) | GOSS Gossamer Bio, Inc. | D. E. Shaw Valence Portfolios, L.L.C. | 27.70M | 5.7% | SCHEDULE 13D/A ↗ |
| Jul 29, 2026 | SCHEDULE 13G/A (amended) | GOSS Gossamer Bio, Inc. | BlackRock, Inc. | 4.89M | 1.0% | SCHEDULE 13G/A ↗ |
| Jul 29, 2026 | SCHEDULE 13G | GOSS Gossamer Bio, Inc. | James Silverman | 24.94M | 5.1% | SCHEDULE 13G ↗ |
| Jul 29, 2026 | SCHEDULE 13G | GOSS Gossamer Bio, Inc. | Opaleye, L.P. | 24.14M | 4.9% | SCHEDULE 13G ↗ |
| Jul 29, 2026 | SCHEDULE 13G | GOSS Gossamer Bio, Inc. | Opaleye Management Inc. | 24.94M | 5.1% | SCHEDULE 13G ↗ |
| Jul 24, 2026 | SCHEDULE 13D/A (amended) | GOSS Gossamer Bio, Inc. | David E. Shaw | 34.61M | 7.1% | SCHEDULE 13D/A ↗ |
| Jul 24, 2026 | SCHEDULE 13D/A (amended) | GOSS Gossamer Bio, Inc. | D. E. Shaw & Co., L.P. | 34.61M | 7.1% | SCHEDULE 13D/A ↗ |
| Jul 24, 2026 | SCHEDULE 13D/A (amended) | GOSS Gossamer Bio, Inc. | D. E. Shaw & Co., L.L.C. | 34.35M | 7.0% | SCHEDULE 13D/A ↗ |
| Jul 24, 2026 | SCHEDULE 13D/A (amended) | GOSS Gossamer Bio, Inc. | D. E. Shaw Valence Portfolios, L.L.C. | 32.64M | 6.7% | SCHEDULE 13D/A ↗ |
| Jul 1, 2026 | SCHEDULE 13D/A (amended) | GOSS Gossamer Bio, Inc. | David E. Shaw | 40.63M | 8.3% | SCHEDULE 13D/A ↗ |
| Jul 1, 2026 | SCHEDULE 13D/A (amended) | GOSS Gossamer Bio, Inc. | D. E. Shaw & Co., L.P. | 40.63M | 8.3% | SCHEDULE 13D/A ↗ |
| Jul 1, 2026 | SCHEDULE 13D/A (amended) | GOSS Gossamer Bio, Inc. | D. E. Shaw & Co., L.L.C. | 40.24M | 8.2% | SCHEDULE 13D/A ↗ |
| Jul 1, 2026 | SCHEDULE 13D/A (amended) | GOSS Gossamer Bio, Inc. | D. E. Shaw Valence Portfolios, L.L.C. | 38.36M | 7.8% | SCHEDULE 13D/A ↗ |
| Jun 11, 2026 | SCHEDULE 13G | GOSS Gossamer Bio, Inc. | Ari Zweiman | 49.87M | 10.0% | SCHEDULE 13G ↗ |
| Jun 11, 2026 | SCHEDULE 13G | GOSS Gossamer Bio, Inc. | 683 Capital Partners, LP | 49.87M | 10.0% | SCHEDULE 13G ↗ |
| Jun 11, 2026 | SCHEDULE 13G | GOSS Gossamer Bio, Inc. | 683 Capital Management, LLC | 49.87M | 10.0% | SCHEDULE 13G ↗ |
| Jun 11, 2026 | SCHEDULE 13D | GOSS Gossamer Bio, Inc. | David E. Shaw | 46.49M | 9.5% | SCHEDULE 13D ↗ |
| Jun 11, 2026 | SCHEDULE 13D | GOSS Gossamer Bio, Inc. | D. E. Shaw & Co., L.P. | 46.49M | 9.5% | SCHEDULE 13D ↗ |
| Jun 11, 2026 | SCHEDULE 13D | GOSS Gossamer Bio, Inc. | D. E. Shaw & Co., L.L.C. | 46.10M | 9.4% | SCHEDULE 13D ↗ |
| Jun 11, 2026 | SCHEDULE 13D | GOSS Gossamer Bio, Inc. | D. E. Shaw Valence Portfolios, L.L.C. | 43.92M | 9.0% | SCHEDULE 13D ↗ |
| Jun 11, 2026 | SCHEDULE 13G | GOSS Gossamer Bio, Inc. | Kai Zheng | 37.67M | 7.7% | SCHEDULE 13G ↗ |
| Jun 11, 2026 | SCHEDULE 13G | GOSS Gossamer Bio, Inc. | DCIG Capital Master Fund LP | 27.65M | 5.7% | SCHEDULE 13G ↗ |
| Jun 11, 2026 | SCHEDULE 13G | GOSS Gossamer Bio, Inc. | Dcig GP LLC | 27.65M | 5.7% | SCHEDULE 13G ↗ |
| Jun 11, 2026 | SCHEDULE 13G | GOSS Gossamer Bio, Inc. | DeepCurrents Investment Group LLC | 37.67M | 7.7% | SCHEDULE 13G ↗ |
| Jun 9, 2026 | SCHEDULE 13G | GOSS Gossamer Bio, Inc. | Context Partners Master Fund, L.P. | 48.84M | 9.9% | SCHEDULE 13G ↗ |
| Jun 9, 2026 | SCHEDULE 13G | GOSS Gossamer Bio, Inc. | Charles E. Carnegie | 48.84M | 9.9% | SCHEDULE 13G ↗ |
| Jun 9, 2026 | SCHEDULE 13G | GOSS Gossamer Bio, Inc. | William D. Fertig | 48.84M | 9.9% | SCHEDULE 13G ↗ |
| Jun 9, 2026 | SCHEDULE 13G | GOSS Gossamer Bio, Inc. | Michael S. Rosen | 48.84M | 9.9% | SCHEDULE 13G ↗ |
| Jun 9, 2026 | SCHEDULE 13G | GOSS Gossamer Bio, Inc. | Context Capital Management, LLC | 48.84M | 9.9% | SCHEDULE 13G ↗ |
| May 14, 2026 | SCHEDULE 13G/A (amended) | GOSS Gossamer Bio, Inc. | Ting Jia | 8.98M | 3.8% | SCHEDULE 13G/A ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 5:58 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances